Skip to main content

Neuroimaging of experimental stroke

RYC-2017-22412

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Incorporación
Call Ramón y Cajal
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION ACHUCARRO BASQUE CENTER FOR NEUROSCIENCE FUNDAZIOA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fluorine Labeling of Nanoparticles and In Vivo 19F Magnetic Resonance Imaging

  • Arango, Juan Manuel
  • Padro, Daniel
  • Blanco, Jorge
  • López-Fernández, Sonia
  • Castellnou, Pilar
  • Villa-Valverde, Palmira
  • Ruiz-Cabello, Jesús
  • Martín, Abraham
  • Carril, Mónica
Fluorinated nanoparticles have increasing applications, but they are still challenging to prepare, especially in the case of water-soluble fluorinated nanoparticles. Herein, a fluorine labeling strategy is presented that is based on the conjugation of custom-made small fluorinated building blocks, obtained by simple synthetic transformations, with carboxylated gold nanoparticles through a convenient phase-transfer process. The synthesis of four fluorinated building blocks with different chemical shifts in 19F nuclear magnetic resonance and varied functionalities is reported, along with their conjugation onto nanoparticles. Fluorinated nanoparticles of small core size obtained by this conjugation methodology and by direct synthesis presented high transverse relaxation times (T2) ranging from 518 to 1030 ms, and a large number of equivalent fluorine atoms per nanoparticle (340-1260 fluorine atoms), which made them potential candidates for 19F magnetic resonance related applications. Finally, nontargeted fluorinated nanoparticles were probed by performing in vivo 19F magnetic resonance spectroscopy (19F MRS) in mice. Nanoparticles were detected at both 1 and 2 h after being injected. 19F MRI images were also acquired after either intravenous or subcutaneous injection. Their fate was studied by analyzing the gold content in tissues by ICP-MS. Thus, the present work provides a general fluorination strategy for nanoparticles and shows the potential use of small fluorinated nanoparticles in magnetic-resonance-related applications., This work was supported in part by grants from the Spanish State Research Agency (MCI/PID2019-107449RB-I00/AEI/10.13039/501100011033, RYC-2017-22412, and SAF2017-84494-C2-R), from the Fundación Biofísica Bizkaia, the Basque Excellence Research Centre (BERC) program, and projects IT1196-19 and Grant KK-2019/bmG19 of the Basque Government. We also thank the UE for funding (Nova MRI, H2020-MSCA-ITN-2018-811382). This work was performed under the Maria de Maeztu Units of Excellence Programme Grant MDM-2017-0720 ministry of Science, Innovation and Universities., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Multimodal imaging of the role of hyperglycemia following experimental subarachnoid hemorrhage

  • Joya, Ana
  • Plaza-García, Sandra
  • Padro, Daniel
  • Aguado, Laura
  • Iglesias, Leyre
  • Garbizu, Maider
  • Gómez-Vallejo, Vanessa
  • Laredo, Carlos
  • Cossío, Unai
  • Torné, Ramon
  • Amaro, Sergio
  • Planas, Anna M.
  • Llop, Jordi
  • Ramos-Cabrer, Pedro
  • Justicia, Carles
  • Martín, Abraham
Hyperglycemia has been linked to worsening outcomes after subarachnoid hemorrhage (SAH). Nevertheless, the mechanisms involved in the pathogenesis of SAH have been scarcely evaluated so far. The role of hyperglycemia was assessed in an experimental model of SAH by T2 weighted, dynamic contrast-enhanced magnetic resonance imaging (T2W and DCE-MRI), [18F]BR-351 PET imaging and immunohistochemistry. Measures included the volume of bleeding, the extent of cerebral infarction and brain edema, blood brain barrier disruption (BBBd), neutrophil infiltration and matrix metalloprotease (MMP) activation. The neurofunctional outcome, neurodegeneration and myelinization were also investigated. The induction of hyperglycemia increased mortality, the size of the ischemic lesion, brain edema, neurodegeneration and worsened neurological outcome during the first 3 days after SAH in rats. In addition, these results show for the first time the exacerbating effect of hyperglycemia on in vivo MMP activation, Intercellular Adhesion Molecule 1 (ICAM-1) expression and neutrophil infiltration together with increased BBBd, bleeding volume and fibrinogen accumulation at days 1 and 3 after SAH. Notably, these data provide valuable insight into the detrimental effect of hyperglycemia on early BBB damage mediated by neutrophil infiltration and MMP activation that could explain the worse prognosis in SAH., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by grants from the Spanish Ministry of Education and Science/FEDER RYC-2017-22412, and PID2019-107989RB-I00, PID2020-118546RB-I00 and La Marató de TV3 (17/C/2017) and by Instituto de Salud Carlos III (PI19/00936, co-funded by the European Regional Development Fund). Jordi Llop also acknowledges the Spanish Research Agency for financial support (MCIN/AEI/10.13039/501100011033; PID2020-117656RB-I00). Part of the work was performed under the Maria de Maeztu Units of Excellence Programme – Grant MDM-2017-0720 funded by MCIN/AEI/10.13039/501100011033. This work was also performed thanks to the human and technical equipment of the Magnetic Resonance Imaging Core facility at IDIBAPS (IBPS15-EE-3688 co-funded by MCIU and by ERDF)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Preclinical validation of human recombinant glutamate-oxaloacetate transaminase for the treatment of acute ischemic stroke

  • Pérez-Mato, María
  • Dopico-López, Antonio
  • Akkoc, Yunus
  • López-Amoedo, Sonia
  • Correa-Paz, Clara
  • Candamo-Lourido, María
  • Iglesias-Rey, Ramón
  • López-Arias, Esteban
  • Bugallo-Casal, Ana
  • da Silva-Candal, Andrés
  • Bravo, Susana B
  • Chantada-Vázquez, María Del Pilar
  • Arias, Susana
  • Santamaría-Cadavid, María
  • Estany-Gestal, Ana
  • Zaghmi, Ahlem
  • Gauthier, Marc A
  • Gutiérrez-Fernández, María
  • Martin, Abraham
  • Llop Roig, Jordi
  • Rodríguez González, Cristina
  • Almeida, Ángeles
  • Migliavacca, Martina
  • Polo, Ester
  • Pelaz, Beatriz
  • Gozuacik, Devrim
  • El Yamani, Naouale
  • SenGupta, Tanima
  • Rundén-Pran, Elise
  • Vivancos, José
  • Castellanos, Mar
  • Díez-Tejedor, Exuperio
  • Sobrino, Tomás
  • Rabinkov, Aharon
  • Mirelman, David
  • Castillo, José
  • Campos, Francisco
The blood enzyme glutamate-oxaloacetate transaminase (GOT) has been postulated as an effective therapeutic to protect the brain during stroke. To demonstrate its potential clinical utility, a new human recombinant form of GOT (rGOT) was produced for medical use. We tested the pharmacokinetics and evaluated the protective efficacy of rGOT in rodent and non-human primate models that reflected clinical stroke conditions. We found that continuous intravenous administration of rGOT within the first 8 h after ischemic onset significantly reduced the infarct size in both severe (30%) and mild lesions (48%). Cerebrospinal fluid and proteomics analysis, in combination with positron emission tomography imaging, indicated that rGOT can reach the brain and induce cytoprotective autophagy and induce local protection by alleviating neuronal apoptosis. Our results suggest that rGOT can be safely used immediately in patients suspected of having a stroke. This study requires further validation in clinical stroke populations., This study was supported by the Instituto de Salud Carlos III_ICIII (grant numbers ICI19/00032, PI20/01014, AC19/00066, and the RICORS-ICITUS network: RD21/0006/0003), Xunta de Galicia (grant number IN607D2020/03), the European Union program FEDER, and the European Regional Development Fund. This study was partially supported under the framework of EuroNanoMed III. A.Z. acknowledges a doctoral scholarship from the INRS/Tunisian Ministry of Education. M.A.G. is a Research Scholar of the Fonds de Recherche du Québec Santé (FRQS, Canada). J.L. thanks the grant AEI-MICINN/PID2020-117656RB-I00. F.C., T.S., and M.G.-F. declare ISCIII Miguel Servet contracts (CPII19/00020, CPII17/00027, and CPII20/0002, respectively). M.P.-M. and A.d.S.-C. declare an ISCIII Sara Borrell contract (CD19/00033 and CD20/00054, respectively). A.M. declare a Ramon y Cajal contract (RYC-2017-22412). B.P. thanks the support of the European Research Council (starting grant #950421) and the Xunta de Galicia (ED431F 2021/02, 2023-PG056, and Centro Singular De Investigación de Galicia Accreditation 2019–2022 (#ED431G 2019/03)., Peer reviewed